2025 - 2026 Genitourinary Oncology Seminar Series
COMING SOON
May 29, 2025
tRNA dosage regulates lineage plasticity and therapy resistance in prostate cancer through codon bias
Yeon Soo Kim, PhD
Post-Doctoral Research Fellow, Hsieh Lab
Fred Hutch Cancer Center
May 22, 2025
Development of a lentiviral-based mouse model to study fitness of somatic mutations/Image-based biomarkers: from prostate MRI to digital pathology
Steven Blinka, PhD and Meera Chappidi MD, MPH
Fred Hutch Cancer Center / University of Washington
May 15, 2025
Exercise for Prostate Cancer Outcomes: From Evidence to Action
Dong-Woo Kang, PhD
Assistant Professor, Public Health Sciences
Fred Hutch Cancer Center
May 8, 2025
Jesse McKenney, MD
Principal Investigator
Cleveland Clinic
May 1, 2025
Targeted Delivery of Biologics
Xiaohu Gao, PhD
Professor, Bioengineering
University of Washington
April 24, 2025
Clinical Utility of the Prostate Health Index in Predicting Outcomes on Active Surveillance
Claire de la Calle, MD
Assistant Professor, Urology
University of Washington
April 17, 2025
Yaw Nyame, MD, MS, MBA
Assistant Professor, Urology
University of Washington
April 10, 2025
Tailoring Radiation Treatment in GU Oncology: Current Strategies and Future Directions
Omar Mian, MD, PhD
Associate Professor, Human Biology
Fred Hutch Cancer Center
April 3, 2025
Characterizing tumor heterogeneity and evolution in bladder cancer rapid autopsies
Gavin Ha, PhD
Associate Professor, Public Health Sciences & Human Biology
Fred Hutch Cancer Center
March 27, 2025
From Liquids to Solids-Developing Tri-Specific Killer Engager Molecules for Prostate Cancer
Nicholas Zorko, MD, PhD
Assistant Professor, University of Minnesota
March 20, 2025
Progress in Prostate Cancer Immunotherapy
Lawrence Fong, MD
Scientific Director, Immunotherapy Integrated Research Center
Fred Hutch Cancer Center
March 13, 2025
The Role of Cystectomy in the Management of NMIBC
John Gore, MD, MS
Professor, Urology
University of Washington
March 6, 2025
Rethinking Preclinical Assumptions: How Clinical Context Shapes Disease Biology and Treatment Response in Prostate Cancer
Kalpit Shah, PhD
Senior Scientist
Genentech
February 27, 2025
Delivering the Cure: Image Guided Delivery of Biomaterials
Avik Som, MD, PhD
Assistant Professor, Radiology
University of Washington
February 20, 2025
Hypoxia and Prostate Cancer Resistance - Take Away the Sugar.
Stephen Plymate, MD
Professor, Medicine/Gerontology
University of Washington
February 13, 2025
Colm Morrissey, PhD
Co-Director, GU Cancer Research Lab
University of Washington
February 6, 2025
Lineage Plasticity in Bladder Cancer
Byron Lee, MD, PhD
Associate Professor, Urology
University of Texas MD Anderson Cancer Center
January 30, 2025
Targeting mRNA Translation in Prostate Cancer
Andrew Hsieh, MD
Associate Director, Human Biology
Fred Hutch Cancer Center
January 23, 2025
Prostate Cancer Active Surveillance and Canary PASS: Updates and Future Directions
Dan Lin, MD
Professor, Urology
University of Washington
January 16, 2025
Prostate Cancer Clinical Research Potpourri: 2024 Conferences Recap
Michael Schweizer, MD
Associate Professor, Clinical Research
Fred Hutch Cancer Center
January 9, 2025
Development and translation of immunotherapeutic approaches for genitourinary malignancies
John K. Lee, MD, PhD
Associate Professor-in-Residence, Hematology/Oncology
University of California, Los Angeles
January 2, 2025
A Deep Learning Framework to Predict Single Gene Expression from Cell-free DNA Methylation
Adil Mohamed, PhD
Post-Doctoral Research Fellow, Haffner Lab
Fred Hutch Cancer Center
December 19, 2024
Transcriptional Condensates as a Promising Tool for Prostate Cancer Therapies
Nada Lallous, PhD
Assistant Professor
University of British Columbia
December 12, 2024
Targeting Epigenetic Vulnerabilities in Prostate Cancer
Michael Haffner, MD, PhD
Assistant Professor, Human Biology & Clinical Research
Fred Hutch Cancer Center
December 5, 2024
Epigenetic Regulation of Lineage Plasticity in Prostate and Bladder Cancer
Michael M. Shen, PhD
Professor, Medical & Urological Sciences
Columbia University
November 14, 2024
Targeting the eIF4E mRNA cap-binding domain induces lineage plasticity in prostate cancer
Rashmi Mishra, PhD
Post-Doctoral Research Fellow, Hsieh Lab
Fred Hutch Cancer Center
November 7, 2024
Translating Molecular Discovery into Therapeutic Approaches in Bladder Cancer
Phillip Palmbos, MD, PhD
Associate Professor, Medical Oncology
University of Michigan
October 31, 2024
Investigating PTGES3 as a Novel Therapeutic Target in Advanced Prostate Cancer
Haolong Li, PhD
Assistant Professor
Human Biology, Fred Hutch Cancer Center
October 17, 2024
Molecular Consequences of Acute versus Chronic CDK12 Loss in Prostate Carcinoma Nominates Distinct Therapeutic Strategies
Sander Frank, PhD
Post-Doctoral Research Fellow, Nelson Lab
Fred Hutch Cancer Center
October 10, 2024
Predictive Modeling of Prostate Cancer Metastasis and Survival: Principles and Examples
Ruth Etzioni, PhD
Professor, Public Health Sciences
Fred Hutch Cancer Center
October 3, 2024
Scratching the Surface: Therapeutics and Theranostics for Bladder Cancer
Jonathan Chou, MD, PhD
Assistant Professor, Hematology/Oncology
University of California San Francisco
September 26, 2024
Pre-diagnostic Circulating Metabolites and Prostate Cancer Risk Across Populations
Harriett Fuller, PhD
Post-Doctoral Research Fellow, Darst Lab
Fred Hutch Cancer Center
September 19, 2024
FZD6 is a Therapeutic Target for Advanced Prostate Cancer
Li Xin, PhD
Professor, Urology
University of Washington Institute for Stem Cell & Regenerative Medicine
September 12, 2024
The Immune Archetypes of Metastatic Prostate Cancer
Peter Nelson, MD
Director, Pacific Northwest Prostate Cancer SPORE
Fred Hutch Cancer Center
2023-2024 Season
June 6, 2024
Urinary Biomarkers for Prostate Cancer
Jonathan Wright, MD, MD, FACS
Professor of Urology
University of Washington
May 23, 2024
Back to the Future: Targeting Molecular Chaperones in Lethal Prostate Cancer
Adam Sharp, PhD
Wellcome Trust Clinical Research Career Development Fellow
Institute of Cancer Research, Surrey, UK
May 16, 2024
Redirecting T Cells to Treat Advanced Prostate Cancer
Jessica Hawley, MD, MS
Assistant Professor of Hematology and Oncology
University of Washington & Fred Hutch Cancer Center
May 2, 2024
Reverse Engineering Curative Treatment Strategies for Advanced Bladder Cancer
Mathew Galsky, MD
Professor of Hematology and Oncology
Mount Sinai Health System
April 25, 2024
Phenotypic Insights, Novel Biomarkers and Pathways in ADT-induced Sarcopenia
Jose Garcia, MD, PhD
Director, Clinical Research Unit
VA Puget Sound Health Care System
April 18, 2024
KRAS-Driven Immune Inhibitory Networks in Pancreatic Cancer
Eric Collisson, MD
Professor, Human Biology
Fred Hutch Cancer Center
April 11, 2024
Molecular Reprogramming Driving Lineage Plasticity in Advanced Prostate Cancer
David Rickman, PhD
Associate Professor
Weill Cornell Medicine
April 4, 2024
Expanding the Actionable Genome
David Solit, MD
Professor of Medicine
Memorial Sloan-Kettering Cancer Center
March 28, 2024
Extrachromosomal DNA, Epigenetic Stochasticity and Tumor Evolution
Chia-Lin Wei, PhD
Professor, University of Washington
March 21, 2024
Prostate Cancer Precision Oncology in the Veteran's Affairs Health Care System
Bruce Montgomery, MD
Professor, University of Washington
March 14, 2024
Jelani Zarif, PhD, MS
Assistant Professor of Oncology, Johns Hopkins University
March 7, 2024
From BCG to Checkpoints: Will we ever achieve precision in immunotherapy for urothelial cancer?
Joshua Meeks, MD, PhD
Associate Professor of Urology, Biochemistry and Molecular Genetics, Northwestern University
February 24, 2024
The Molecular Imaging Correlates of PSMA Radioligand Therapy
Amir Iravani, MD
Associate Professor of Radiology, University of Washington
February 15, 2024
Veda Giri, MD, PhD
Division Chief, Clinical Cancer Genetics; Yale School of Medicine
February 8, 2024
Decoding the Complexities of Androgen Receptor Transcription in Prostate Cancer
Nathan Lack, PhD
Assistant Professor, University of British Columbia
February 1, 2024
HER2 as a Bladder Cancer Target: Better Drugs can Revive an Old Target;
Antibody Drug Conjugates for Prostate Cancer: Lessons Learned from Bladder Cancer
Evan Yu, MD
Professor, University of Washington
January 18, 2024
Advancing Precision Therapies for Metastatic Prostate Cancer
Ruben Raychaudhuri, MD
Hematology-Oncology Fellow, Fred Hutch Cancer Center
January 11, 2024
Epigenetic Therapies for mCRPC
Michael Schweizer, MD
Associate Professor, University of Washington
January 4, 2024
AIM High: Epigenetic Modulation and Immune Stimulation in Bladder Cancer
Elizabeth Koehne, MD
Acting Instructor, Urologic Oncology
Fred Hutch Cancer Center
December 14, 2023
Exome sequencing studies implicate germline genetic risk factors for aggressive prostate cancer
Burcu Darst, PhD
Assistant Professor
Fred Hutch Cancer Center
December 7, 2023
Targeting DNA Repair Deficiency in Genitourinary Cancers
Kent Mouw, MD, PhD
Assistant Professor
Harvard Medical School
November 16, 2023
Galina Semenova, PhD
Post Doctoral Fellow, Fred Hutch Cancer Center
Robert Patton, PhD
Post Doctoral Fellow, Fred Hutch Cancer Center
November 9, 2023
Harnessing Clinical Genetic Testing for Prostate Cancer
Colin Pritchard, MD, PhD
Director, Genetics and Solid Tumors Lab, University of Washington
November 2, 2023
Agonising Over Antagonising the Androgen Receptor
Wayne Tilley, PhD
Director, Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide
October 19, 2023
Neuroendocrine Prostate Cancer - What Are We Talking About?
Michael Haffner, MD, PhD
Assistant Professor, Human Biology Division, Fred Hutch Cancer Center
October 12, 2023
Clinical Biomarkers and Immune Checkpoint Inhibitors (ICI) in Advanced Urothelial Carcinoma
Dimitra Bakaloudi, PhD
Post-Doctoral Research Fellow, University of Washington
Targeting Mechanisms of mRNA Translation Initiation for Cancer Therapy
Patrick Hoang
Research Technician, Fred Hutch Cancer Center
October 5, 2023
When the Square Became a Sphere: A Pathologist’s Journey
Lawrence True, MD
Professor of Pathology, University of Washington
September 28, 2023
Wolfgang Weber, MD
Director of Nuclear Medicine, Technical University Munich
September 21, 2023
Peter S. Nelson, MD
Director, Pacific Northwest Prostate Cancer SPORE
Fred Hutch Cancer Center
2022-2023 Season
June 1, 2023
Jing Zeng, MD
Associate Professor, University of Washington
May 25, 2023
Nondestructive 3D Pathology and Analysis for Precision Medicine
Jonathan Liu, PhD
Professor, University of Washington
May 18, 2023
Joshi Alumkal, MD
Professor, University of Michigan
May 11, 2023
Community-Partnered and Patient-Centered Approaches to Addressing Inequities in Prostate Cancer Care among Black Individuals
Yaw Nyame, MD, MS, MBA
Assistant Professor, Fred Hutch Cancer Center
May 4, 2023
Sarah Psutka, MD
Associate Professor, University of Washington
April 27, 2023
Exploiting DNA Damage Repair Alterations in Advanced Prostate Cancer
Heather Cheng, MD, PhD
Assistant Professor, University of Washington
April 20, 2023
Biomolecular Condensates and Stress Adaptation in Cancer
Syam Somasekharan, PhD
Assistant Professor, University of British Columbia
April 13, 2023
Exploiting DNA Damage Repair Alterations in Advanced Prostate Cancer
Ruben Raychaudhuri, PhD
Post-Doctoral Fellow, Fred Hutch
April 6, 2023
Urologic Cancer Care in the WWAMI Catchment
John Gore, MD
Professor, University of Washington
March 30, 2023
Common and Rare Germline Genetic Contributions to Overall and Aggressive Prostate Cancer Risk
Elizabeth Wasmuth, PhD
Assistant Professor, University of Texas San Antonio
March 23, 2023
Leveraging Insights into PSMA Biology to Optimize PSMA Directed Therapies
Michael Haffner, MD, PhD
Assistant Professor, Fred Hutch Cancer Center
March 9, 2023
Improving Quality in Cancer Care: Addressing Access to Care and Reducing Disparities in GU Oncology
Evan Yu, MD
Assistant Professor, University of Washington
March 2, 2023
New Approaches in the Treatment of Bladder Cancer
Jonathan Rosenberg, MD
Chief, GU Oncology, Memorial Sloan Kettering Cancer Center
February 23, 2023
Effects of the Great Oxygenation Event and Other Metabolic Interventions for Prostate Cancer
Stephen Plymate, MD
Professor, University of Washington
February 16, 2023
Common and Rare Germline Genetic Contributions to Overall and Aggressive Prostate Cancer Risk
Burcu Darst, PhD
Assistant Professor, Fred Hutch Cancer Center
February 9, 2023
Elahe Mostaghel, MD, PhD
Associate Professor, University of Washington
February 2, 2023
The Dilemma of T1 NBIBC
Sima Porten, MD, MPH
Associate Professor, University of California San Francisco
January 26, 2023
Bipolar Androgen Therapy v2.0: Updates and Future Directions
Michael Schweizer, MD
Associate Professor, University of Washington
January 19, 2023
Exploration of Novel Therapy for Patients with Thoracic and GU Cancers
Lingbin Meng, MD, PhD
Moffitt Cancer Center
January 12, 2023
Improving Quality in Cancer Care: Addressing Access to Care and Reducing Disparities in GU Oncology
Hiba Khan, MD
Fred Hutch Cancer Center
December 15, 2022
Chromatin Variants Identify Cancer Drivers in the Repetitive Genome
Mathieu Lupien, PhD
Professor, University of Toronto
December 8, 2022
Tumor Cell-intrinsic and Extrinsic Determinants for Prostate Cancer Aggressiveness
Li Xin, PhD
Professor, University of Washington
November 17, 2022
Effects of Fluid Shear Stress on Circulating Tumor Cells
Michael Henry, PhD
Professor, University of Iowa
November 3, 2022
The Transformative Journey Towards Precision Pathology: Challenges and Opportunities
George Netto, MD
Professor, University of Alabama Birmingham
October 20, 2022
Deciphering and Exploiting Genomic and Metabolic Alterations in Prostate Cancer
Ian Mills, PhD
Professor, University of Oxford
October 13, 2022
New Therapeutic Discoveries and Mechanisms for Castrate Resistant Prostate Cancer
Kathleen Kelly, PhD
Chief, Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute
October 6, 2022
Updates on the UW/Fred Hutch bladder cancer program; Bladder Cancer Rapid Autopsy
Andrew Hsieh, MD, and Ming Lam, PhD
University of Washington/Fred Hutch
September 29, 2022
Modelling and Targeting CRPC or NEPC progression from Hormone-Naïve Prostate Cancer
Yuzhuo Wang, PhD, FCAHS
Distinguished Scientist, BC Cancer Research Center
September 22, 2022
Dual Targeting of HDAC and PI3K in Metastatic Castration-Resistant Prostate Cancer
John K. Lee, MD, PhD
Assistant Professor, Fred Hutch Cancer Center/University of Washington
September 15, 2022
Prostate Cancer 2022: The Bright Road Ahead
Matthew Cooperberg, MD, MPH
Professor, University of California San Francisco
September 8, 2022
Building a Prostate Cancer Dependency Map
Peter Nelson, MD
Director, Pacific Northwest Prostate Cancer SPORE
June 23, 2022
Defining the Roles of Genetic Factors in the Cellular Reprogramming of Androgen Receptor-Active Prostate Cancer to Neuroendocrine Prostate Cancer
Shan Li, PhD
Post-Doctoral Research Fellow, Fred Hutch Cancer Center
June 23, 2022
Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer
Reza Ghodsi, PhD
Post-Doctoral Research Fellow, Fred Hutch Cancer Center
June 16, 2022
2022 ASCO Updates
Michael Schweizer, MD
Assistant Professor, University of Washington
June 9, 2022
Androgen Receptor Regulation of Luminal and Non-Luminal Cell Identities in Prostate Cancer
Stephanie Harmon, PhD
Staff Scientist, National Institutes of Health
June 2, 2022
ADUX4 and the Elusive Cancer Stem Cell
Stephen Tapscott, MD, PhD Professor, Fred Hutch Cancer Center
May 26, 2022
Androgen Receptor Regulation of Luminal and Non-Luminal Cell Identities in Prostate Cancer
Scott Dehm, PhD
Assistant Professor, University of Minnesota
May 12, 2022
HOXB13 Alters Chromatin Accessibility in Prostate Cancer Through Interactions with the SWI/SNF Complex
Nathan Lack, PhD
Assistant Professor, University of British Columbia
May 5, 2022
Exploring Bladder Cancer Biology in Mouse and Man
William Kim, MD
Professor, University of North Carolina
April 28, 2022
Architectural Diversity of Prostate Cancer Bone Metastasis
Michael Cox, PhD
Professor, University of British Columbia
April 21, 2022
The Microbiome as a Mediator of Prostate Carcinogenesis
Karen Sfanos, MS, PhD
Associate Professor, Johns Hopkins Medicine
April 14, 2022
Overcoming Resistance Mechanisms of AR-targeted Therapy
Allen Gao, MD, PhD
Professor, University of California Davis
April 7, 2022
Noah M. Hahn, MD
Professor, Johns Hopkins Greenberg Bladder Cancer Institute
March 17, 2022
Cellular Heterogeneity in the Therapeutic Resistance and Disease Progression of Prostate Cancer – A Pathologist’s Perspective
Jiaoti Huang, MD, PhD
Professor, Duke University
March 10, 2022
Protein Control Using Targeted Degradation Approaches
Benham Nabet, PhD
Assistant Professor, Fred Hutch Cancer Center
March 3, 2022
The (R)evolution in Urothelial Cancer Treatment Changng Practice via Collaborative Research
Petros Grivas, MD, PhD
Associate Professor, Division Medical Oncology, University of Washington
Associate Professor, Clinical Research Division, Fred Hutch
February 17, 2022
Novel Insights in Prostate Cancer Growth
Hannelore Heemers, PhD
Associate Staff, Cleveland Clinic/Lerner Research Institute
February 10, 2022
Germline Genetic Factors as Predictors of Prostate Cancer Risk in Multi-Ancestry Populations
Burcu Darst, PhD
Assistant Professor, Fred Hutch Cancer Center
February 3, 2022
Investigating Genetic Determinants of Bladder Cancer and New Therapeutic Approaches
John K. Lee, MD, PhD
Assistant Professor, Fred Hutch Cancer Center
January 27, 2022
Functional Genomics of Untranslated Regions in Prostate Cancer
Samantha Schuster
PhD Candidate, University of Washington
Andrew Hsieh MD
Associate Professor, Fred Hutch Cancer Center
January 20, 2022
Precision Medicine with DNA-targeted Therapies
Yves Pommier, MD, PhD
Principal Investigator, National Institutes of Health
January 13, 2022
TP53 Germline Mutations Are Associated with Prostate Cancer
Kara Maxwell, MD, PhD
Associate Professor, Penn Medicine
Colin Pritchard, MD, PhD
Director, Genetics and Solid Tumors Laboratory, University of Washington
January 6, 2022
mTOR Signaling Effects in Urothelial Carcinoma
Donna Hansell, MD, PhD
Professor, Oregon Health and Science University
December 2, 2021
Artificial General Intelligence: A Profoundly Disruptive Approach to Unmet Needs in Health and Wellness
Craig Mundie
CEO, Mundie &Associates
November 18, 2021
Phenotype to Targeted Therapy: Problems and Pathways to Drug Development
Stephen Plymate, MD
Professor, University of Washington
November 4, 2021
Exploiting Urine Derived DNA for the Assessment of Bladder Cancer Using High Accuracy Sequencing
Scott R. Kennedy, PhD
Assistant Professor, University of Washington
October 21, 2021
Developmental Pathways and Prostate Cancer: The Role of HOXB13 Binding Partners in Prostate Progression
Donald Vander Griend, PhD
Associate Professor, University of Illinois at Chicago
October 14, 2021
Longitudinal Single-Cell Analysis Of Metastases From Men With mHSPC Treated with ADT and Anti-PD1
Jessica Hawley, MD
Assistant Professor, Fred Hutch Cancer Center
October 7, 2021
Germline-Somatic Interactions in UC Genomes
Bishoy Faltas, MD
Assistant Professor, Weill Cornell Medicine
September 30, 2021
Widening the aperture: A role for T cell intrinsic androgen receptor activity
Amy Moran, PhD
Associate Professor, Oregon Health and Science University
September 23, 2021
Cellular Plasticity in Prostate Cancer Treatment Resistance
Amina Zoubeidi, PhD
Professor, University of British Columbia
September 16, 2021
Deciphering the Mechanism of Lineage Plasticity-Driven AR Therapy Resistance at Single Cell Resolution
Ping Mu, PhD
Assistant Professor, UT Southwestern Medical Center
September 9, 2021
Convergent Evolution and the Origins of Lethal Cancer:the Polyaneuploid Cancer Cell State
Kenneth Pienta, MD
Professor, Johns Hopkins Medicine
September 2, 2021
Molecular Classification of Prostate Cancer: Insights for Precision Oncology
Pete Nelson, MD
Director, Pacific Northwest Prostate Cancer SPORE